Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360-degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of ear infection
3.2.1.2 Growing advancements in medical technology
3.2.1.3 Rising government initiatives and policies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Increasing antibiotic resistance
3.2.2.2 High cost associated with surgery
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter’s analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Infection Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Middle ear
5.3 Outer ear
5.4 Inner ear
Chapter 6 Market Estimates and Forecast, By Pathogen, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Bacteria
6.3 Virus
6.4 Fungus
Chapter 7 Market Estimates and Forecast, By Treatment, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Surgery
7.3 Medication
7.3.1 Antibiotics
7.3.2 Analgesics
7.3.3 Antiviral
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Topical
8.3 Oral
8.4 Otic
8.5 Other routes of administration
Chapter 9 Market Estimates and Forecast, By End-use, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital
9.3 ENT clinics
9.4 Homecare settings
9.5 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Candela Healthcare Private Limited
11.2 Cipla Ltd.
11.3 Dr. Reddy's Laboratories
11.4 FDC Limited
11.5 Glenmark Pharmaceuticals Limited
11.6 Leeford Healthcare Ltd.
11.7 Novartis AG
11.8 Pfizer Inc.
11.9 Sanofi SA
11.10 Sun Pharmaceutical Industries Ltd.
11.11 Torque Pharmaceuticals Pvt. Ltd.
11.12 Torrent Pharmaceuticals
11.13 WraSer Pharmaceuticals
